The true role of the central lab in 2026: As decentralized diagnostics grows, what's actually changing?

Vatsal Tiwari; Director, Healthcare Strategy

Key Takeaways 

Every time a new point of care (POC) device hits the market, the same narrative resurfaces: the central lab is dead. The assumption is that decentralization is winning and the future belongs to whoever can fit a diagnostic test into a physician’s pocket.   

But the data reveals a more nuanced reality. The growth numbers for POC are massive, but the substitution story is a myth. Decentralized testing and central labs aren't competing for the same job. For product leaders and manufacturers developing diagnostic platforms, understanding this distinction is the key to building tools clinicians actually adopt.  

The growth is real, but so is lab consolidation 

POC diagnostics is undeniably booming. Driven by chronic disease management and the demand for immediate, bedside answers, industry estimates put the global market on track to climb from $21.7 billion in 2025 to nearly $29.9 billion by 2033. (i)

However, central labs aren't shrinking to make room. Industry estimates put the global clinical laboratory services market on track toward $510 billion by 2033 (ii), and capital is actively flowing into lab consolidation, not away from it: Quest Diagnostics acquired Spectra Laboratories' assets in 2025 (iii), and its Corewell Health joint venture closed in January 2026 (iv).  

If central labs were becoming obsolete, capital wouldn't be flowing into acquiring more of them. 

Why physicians still lean on the lab 

Market size is one thing, but physician behavior tells the real story. When a rapid strep test comes back negative but clinical suspicion remains high, physicians still send a PCR to the lab. This isn't habit, it's a rational safeguard: POC platforms trade some analytical performance for speed, and regulators agree. CLIA's 2024 Final Rule tightened personnel standards for POC (v), and 2025 proficiency changes for analytes like hemoglobin A1C set stricter accuracy thresholds (vi). The central lab remains the accuracy benchmark. 

The result: central labs are losing exclusivity, not relevance. They're now one node, often still the most trusted node, in a network that also includes point of care devices, home testing kits, and continuous monitoring. Physicians have adapted accordingly, using decentralized tools for triage and screening, and reserving the lab for confirmation and complex cases where a wrong answer carries real consequences. 

This is specialization, not obsolescence. 

What this means for go to market strategy  

For MedTech manufacturers, this shift in the lab's role demands a new playbook: 

1. Connectivity earns physician trust 
Data integration is no longer optional: it's how decentralized results earn physician trust. A POC device that doesn’t integrate smoothly into an EHR workflow or automatically trigger lab confirmation when a result needs it, is essentially asking physicians to operate on blind faith. 

2. The real opportunity is referral, not replacement 
POC testing and the central lab don't compete for volume. They feed each other: POC generates central lab referrals, and central labs generate POC follow up, running in both directions. The stronger position enables the handoff: decentralized for the first read, centralized for the confirmatory or complex case, with data flowing seamlessly between them. 

3. Design assuming physicians start skeptical 
Demonstrated analytical performance under real world conditions earns physician trust. Marketing claims of "lab quality accuracy" don't. Physicians are trained to verify, so prove performance in clinical conditions before you claim it in marketing. 

Looking ahead

The next generation platforms that win won't pick a side of this divide. They'll make it invisible to the physician, blending the decentralized first read with the lab's confirmation into one seamless result. 

Phronesis’ Medical Diagnostics and broader Healthcare Research teams study exactly this: how physicians build trust in a result, and where that trust breaks down. 

Sources:

[i] Grand View Research, market sizing report on the global point of care diagnostics market, 2025 to 2033

[ii] Coherent Market Insights, market sizing report on the global clinical laboratory services market, 2026 to 2033

[iii] Quest Diagnostics newsroom: Quest Diagnostics Completes Acquisition of Clinical Testing Assets from Fresenius Medical Care, August 5, 2025

[iv] Corewell Health and Quest Diagnostics Complete Laboratory Joint Venture Transaction in Michigan, January 5, 2026

[v] Centers for Medicare & Medicaid Services, Final Rule CMS-3326-F (personnel qualifications)